Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. News
  7. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaxcyte to Present at Upcoming Investor Conferences

11/11/2021 | 04:06pm EST

FOSTER CITY, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in and host one-on-one meetings at the following virtual investor conferences:

Jefferies London Healthcare Conference
November 16 – 19, 2021

  • Fireside Chat available on-demand starting Thursday, November 18 at 3:00am ET.

Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29 – December 2, 2021

  • Fireside Chat available on-demand starting Monday, November 22 at 10:00am ET.

Evercore ISI 4th Annual HealthCONx Virtual Conference
November 30 – December 2, 2021

  • Fireside Chat will take place live on Wednesday, December 1 at 4:45pm ET.

The webcast of these presentations can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of each webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com


All news about VAXCYTE, INC.
01/13VAXCYTE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/13AFTER HOURS WATCH LIST SCORECARD : Kbh, pcvx, estc
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
01/13Health Care Stocks Fading Thursday as Biotechs Stumble
MT
01/13Health Care Stocks Mixed Pre-Bell Thursday
MT
01/13Vaxcyte Prices Offering of Common Shares, Warrants; Expects $100 Million Gross Proceeds
MT
01/13Vaxcyte Announces Pricing of $100 Million Public Offering
GL
01/13Vaxcyte Announces Pricing of $100 Million Public Offering
GL
01/12MT NEWSWIRES AFTER HOURS WATCH LIST : Kbh, pcvx, estc
MT
01/12Vaxcyte Launches Public Offering of Shares, Warrants; Stock Plunge After-Hours
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -100 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,29x
Yield 2021 -
Capitalization 969 M 969 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 969x
Nbr of Employees 58
Free-Float -
Chart VAXCYTE, INC.
Duration : Period :
Vaxcyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXCYTE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 17,53 $
Average target price 50,50 $
Spread / Average Target 188%
EPS Revisions
Managers and Directors
Grant E. Pickering Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
Carlos V. Paya Chairman
Romulo Colindres Chief Medical Officer
Jim Wassil Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VAXCYTE, INC.-26.31%969
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.95%47 873
BIONTECH SE-37.66%38 812